Aegr-733    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
79Homozygous familial hypercholesterolemia4

79. Homozygous familial hypercholesterolemia    [ 128 clinical trials,   105 drugs,   (DrugBank: 29 drugs),   8 drug target genes,   15 drug target pathways]
Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 128 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-003806-33-GR
(EUCTR)
30/06/201624/03/2016A clinical study in Pediatric Patients with Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy conducted to assess safety, tolerability and efficacy of Lomitapide A Phase 3, Single-arm, Open-label, International, Multi-center Study to Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy Homozygous familial hypercholesterolemia (HoFH).
MedDRA version: 18.1;Level: LLT;Classification code 10057080;Term: Homozygous familial hypercholesterolemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: lomitapide
Product Code: AEGR-733
INN or Proposed INN: LOMITAPIDE
Product Name: lomitapide
Product Code: AEGR-733
INN or Proposed INN: LOMITAPIDE
Product Name: lomitapide
Product Code: AEGR-733
INN or Proposed INN: LOMITAPIDE
Product Name: lomitapide
Product Code: AEGR-733
INN or Proposed INN: LOMITAPIDE
Aegerion Pharmaceuticals Inc.NULLNot RecruitingFemale: yes
Male: yes
45Phase 3Canada;Greece;Turkey;Austria;Israel;Germany;Italy
2EUCTR2010-023742-79-IT
(EUCTR)
25/03/201121/02/2011A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor ‘lomitapide’ (AEGR-733) in Patients with Homozygous Familial Hypercholesterolemia - NDA Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor ‘lomitapide’ (AEGR-733) in Patients with Homozygous Familial Hypercholesterolemia - ND Homozygous Familial Hypercholesterolemia
MedDRA version: 9.1;Level: LLT;Classification code 10057080
Product Name: Lomitapide
Product Code: AEGR-733
Product Name: Lomitapide
Product Code: AEGR-733
AEGERION PHARMACEUTICALSNULLNot RecruitingFemale: yes
Male: yes
23Phase 3Italy
3EUCTR2008-007058-36-IT
(EUCTR)
25/06/200903/06/2009A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients with Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy - NDA Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients with Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy - ND Homozygous Familial Hypercholesterolemia
MedDRA version: 9.1;Level: LLT;Classification code 10048373;Term: Hypercholesterolaemia aggravated
Product Code: AEGR-733
Product Code: AEGR-733
Aegerion PharmaceuticalsNULLNot RecruitingFemale: yes
Male: yes
25Phase 3Italy
4NCT00730236
(ClinicalTrials.gov)
December 20076/8/2008A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering TherapyHomozygous Familial HypercholesterolemiaDrug: AEGR-733Aegerion Pharmaceuticals, Inc.FDA Office of Orphan Products DevelopmentCompleted18 YearsN/AAll29Phase 3United States;Canada;Italy;South Africa